文献速递慢性肾脏病肾血管病与高血压

用尿液蛋白质组学预测2型糖尿病合并高血压患者对螺内酯治疗的 albuminuria 反应

Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

该研究为双盲随机临床试验的事后分析,57例接受螺内酯12.5-50 mg/日、54例接受安慰剂治疗16周。螺内酯较安慰剂降低尿白蛋白/肌酐比值(UACR)50%,但个体间变异大。基线CKD273蛋白质组分类器与治疗分配存在交互作用,高CKD273分位组UACR降低幅度更大。

要点

  • 螺内酯较安慰剂降低UACR 50%,但个体间反应变异大(第5至95百分位,7%至312%)。
  • CKD273与治疗分配存在交互作用(β=-1.09,P=0.026)。
  • 基线CKD273最高三分位组UACR降低63%,其余两分位组合并降低16%(P=0.011)。

核心结论

  • 尿液蛋白质组学分类器可用于识别更可能对螺内酯治疗表现出白蛋白尿降低反应的2型糖尿病患者。
  • 这些结果提示尿液蛋白质组学可能是定制治疗的有价值工具,但需要在更大规模的临床试验中确认。

研究设计与样本

  • 一项双盲随机临床试验的事后分析。
  • 患者随机分配至螺内酯12.5-50 mg/日(n=57)或安慰剂(n=54)治疗16周。
  • 患者诊断为2型糖尿病和难治性高血压,治疗为肾素-血管紧张素系统抑制的辅助治疗。
  • 主要终点为尿白蛋白/肌酐比值(UACR)的百分比变化。
  • 基线时采用毛细管电泳质谱法量化尿液肽段,使用基于273种已知尿液肽段的CKD273蛋白质组分类器。

主要发现

  • 螺内酯较安慰剂降低UACR 50%,但UACR反应个体间变异大(第5至95百分位,7%至312%)。
  • 检测到CKD273与治疗分配之间的交互作用(β=-1.09,P=0.026)。
  • 基线CKD273较高与螺内酯组UACR较大降低相关(β=-0.70,P=0.049),安慰剂组无此关联(β=0.39,P=0.25)。
  • 按基线CKD273三分位分层,最高三分位组UACR降低63%(95%置信区间:35-79%),其余两分位组合并降低16%(-17至40%)(P=0.011)。

局限性

  • 这些结果需要在更大规模的临床试验中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The mineralocorticoid receptor antagonist spironolactone significantly reduces albuminuria in patients with diabetes. Prior studies have shown large between-patient variability in albuminuria treatment response. We previously developed and validated a urinary proteomic classifier that predicts onset and progression of chronic kidney disease. Here, we tested whether the proteomic classifier based on 273 urinary peptides (CKD273) predicts albuminuria response to spironolactone treatment. METHODS: We performed a post hoc analysis in a double-blind randomized clinical trial with allocation to either spironolactone 12.5-50 mg/day (n = 57) or placebo (n = 54) for 16 weeks. Patients were diagnosed with type 2 diabetes and resistant hypertension. Treatment was an adjunct to renin-angiotensin system inhibition. Primary endpoint was the percentage change in urine albumin to creatinine ratio (UACR). Capillary electrophoresis mass spectrometry was used to quantify urinary peptides at baseline. The previously validated combination of 273 known urinary peptides was used as proteomic classifier. RESULTS: Spironolactone reduced UACR relative to placebo by 50%, although with a large between-patient variability in UACR response (5th to 95th percentile, 7 to 312%). An interaction was detected between CKD273 and treatment assignment (β = -1.09, P = 0.026). Higher values of CKD273 at baseline were associated with a larger reduction in UACR in the spironolactone group (β = -0.70, P = 0.049), but not in the placebo group (β = 0.39, P = 0.25). Stratified in tertiles of baseline CKD273, reduction in UACR was greater in the highest tertile, 63% (95% confidence interval: 35-79%), as compared with the two other tertiles combined, 16% (-17 to 40%) (P = 0.011). CONCLUSIONS: A urinary proteomics classifier can be used to identify individuals with type 2 diabetes who are more likely to show an albuminuria-lowering response to spironolactone treatment. These results suggest that urinary proteomics may be a valuable tool to tailor therapy, but confirmation in a larger clinical trial is required.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Lindhardt M, Persson F, Oxlund C, et al. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. Nephrol Dial Transplant. 2018. PMID: 28064163. doi:10.1093/ndt/gfw406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。